CHEALTGE

Nanjing Healed Gene Biotechnology Co., Ltd. was established in October 2023, focusing on the detection and treatment of depression. Future operations will concentrate on the entire field of brain science. Currently, the company has completed the development of technical platforms including fluorescent quantitative PCR, molecular fluorescence hybridization, nucleic acid drugs, and other blood and saliva sample technologies. These platforms can be used for rapid quantitative diagnosis and risk assessment of depression, providing objective biological indicators for depression diagnosis, and can be applied in scenarios such as in-hospital diagnosis, out-of-hospital physical examinations, and public self-testing.